Will Pfizer divest a big chunk of its operations?

Pfizer's ($PFE) new CEO Ian Read might want to trim certain business units to morph the drug giant into a pure pharmaceutical research company like Eli Lilly ($LLY), Forbes' Matthew Herper writes today, citing recent note from Bernstein Pharmaceuticals analyst Tim Anderson. The analyst wrote that the strategy could mean transactions that would divest businesses that account for 40 percent or $32 billion of Pfizer's $67 billion in annual sales, according to Herper's piece. Story

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.